DOCSLIB.ORG

The Global Fight Against Avian Influenza Lessons for the Global Management of Health and Environmental Risks and Crises

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Global Fight Against Avian Influenza Lessons for the Global Management of Health and Environmental Risks and Crises The Global Fight Against Avian Influenza Lessons for the Global Management of Health and Environmental Risks and Crises Aline Leboeuf February 2009 les Health and Environment Reports n° 2 rapports The Institut Français des Relations Internationales (Ifri) is a research center and a forum for debate on major international political and economic issues. Headed by Thierry de Montbrial since its founding in 1979, Ifri is a non-governmental and a non-profit organization. As an independent think tank, Ifri sets its own research agenda, publishing its findings regularly for a global audience. Using an interdisciplinary approach, Ifri brings together political and economic decision-makers, researchers and internationally renowned experts to animate its debate and research activities. With offices in Paris and Brussels, Ifri stands out as one of the rare French think tanks to have positioned itself at the very heart of European debate. The opinions expressed in this text are the responsibility of the author alone. ISBN : 978-2-86592-408-0 © All rights reserved, Ifri, 2009 IFRI IFRI-BRUSSELS 27 RUE DE LA PROCESSION RUE MARIE-THÉRÈSE, 21 75740 PARIS CEDEX 15 - FRANCE 1000 - BRUSSELS, BELGIUM TÉL. : 33 (0)1 40 61 60 00 TÉL. : 00 + (32) 2 238 51 10 FAX: 33 (0)1 40 61 60 60 Email: [email protected] Email: [email protected] WEBSITE: www.ifri.org THE HEALTH & ENVIRONMENT REPORTS The “Health and Environment: from Safety and Security Issues to New Governance Options?” programme of Ifri seeks to elucidate the linkages that can exist between health and environmental issues and security considerations, and to analyse the impacts of such linkages in terms of efficiency and of the governance options available to international actors. The programme also wishes to stimulate a wider debate within the global civil society and bring to the fore innovative perspectives on these issues, through the linking together of practitioners within a dedicated network. As part of the Health and Environment programme of Ifri, a minimum of three case-studies on global health and environmental issues are published each year: the Health & Environment Reports . All reports have an empirical, comparative and policy-oriented approach, and comprise: - An empirical analysis of the health and/ or environmental issue under study; - A prospective analysis of the future developments of the issue under study; - Policy-oriented recommendations. The Health and Environment programme of Ifri is supported by the Taipei Representative Office in France. Editorial Board: Editor: Aline Leboeuf Deputy Editor: Emma Broughton Layout assistant: Cécile Grima CONTENTS EXECUTIVE SUMMARY ...............................................................5 ABBREVIATIONS .......................................................................9 INTRODUCTION .......................................................................13 FIGHTING AI, A DIGEST ...........................................................19 ON THE HUMAN AND ANIMAL FRONT : MULTISECTORAL ISSUES ................. 19 From a vertical approach to “One World, one Health”? .........................................................................20 Communication ..........................................................................................................................................22 The transparency requirement.................................................................................................................23 The right message and the right vector for the right audience .................................................................25 Surveillance ................................................................................................................................................29 Global surveillance, a strong improvement ..............................................................................................29 At the country level, different approaches to surveillance systems..........................................................30 Emergency versus development ..............................................................................................................36 Research .....................................................................................................................................................39 Norms and guidelines: development and implementation.....................................................................42 Health and Environment Reports , n° 2, February 2009 The Global Fight against Avian Influenza CONTROLLING AI OUTBREAKS ON THE ANIMAL FRONT ............................. 49 Culling and the compensation issue ........................................................................................................49 Vaccination .................................................................................................................................................51 The food chain and Biosecurity................................................................................................................53 The wild card: wild birds and the ecosystem ..........................................................................................54 ON THE HUMAN FRONT : T OWARDS GLOBAL HEALTH SECURITY ?............... 57 Responding to the H5N1 outbreaks in humans.......................................................................................57 Pandemic preparedness............................................................................................................................63 Virus-sharing issue: a North/South debate?............................................................................................71 GOVERNING THE FIGHT AGAINST AI.........................................77 A MULTIPLAYER GAME ......................................................................... 79 States and national actors: the raw material of any global initiative.....................................................79 Intergovernmental organisations: the cement to support the global governance process ................83 The regional level: a facilitating level.......................................................................................................86 LEARNING FROM SPECIFIC AI G OVERNANCE OPTIONS ............................. 88 Mobilising a lasting international momentum .........................................................................................88 Coordinating a global fight........................................................................................................................92 2 / 119 Health and Environment Reports , n° 2, February 2009 The Global Fight against Avian Influenza CONCLUSION : A FORESIGHT ATTEMPT .....................................97 RECOMMENDATIONS .............................................................101 INTERVIEWS ..........................................................................107 BIBLIOGRAPHY .....................................................................111 3 / 119 EXECUTIVE SUMMARY The term “Avian Influenza” (AI) refers both to: 1/ the existing and related avian influenza epizooty and epidemic, and 2/ the possibility of an influenza pandemic, that would result from a mutation of the H5N1 virus. The issue of AI therefore implies two necessities: 1/ the need to control the existing avian influenza virus and 2/ the need to prepare for the next pandemic. The reaction to the AI issue has thus articulated itself, over the years, in two movements: 1/ a strong solidarity drive, from the better prepared, to the less prepared and 2/ a “national preparedness drive”, as the majority of countries strove to strengthen their own capacity to respond to an AI outbreak/pandemic. The tension between those two dimensions of the management of AI contributed to the build-up of a strong mobilisation, from very different communities (animal health, human health, environmental health, security, media, private sector, etc.). This process of mobilisation resulted in the emergence of what appears to be, with the benefit of hindsight, a real “global fight against avian influenza”, which reaps significant results, as this report highlights. Such a dynamic may not last forever, however, as a lurking fatigue with the issue seems to be spreading amongst actors, and threatening past and current efforts. The new “One World One Health” agenda could, in this regard, prove to be a necessary option to remobilise actors, and consolidate the outcomes of the fight against AI. Before highlighting some key lessons from the fight against AI, one should draw some key features of the architecture of the global governance of avian influenza. Which Global Governance of AI? - Governing AI at the global level has been a fluid process , as it took some time to structure the large range of actors that had mobilised. Today still, as the agenda One World One Health is gains momentum, the exact role played by the different institutions involved in this process might start to shift again. - States are the key actors , as they raise political momentum at the global level, and as no possible response/control/preparedness is possible without them. Health and Environment Reports , n° 2, February 2009 The Global Fight against Avian Influenza - Intergovernmental Organisations are very important supporting actors in the fight against AI; it is important in this regard to understand their role and limits. If IOs are faced with some problems (i.e. bureaucratic problems, traditional aid issues), they also proved to
Load more

Recommended publications
  • Developing Countries, Vaccine Access and Influenza Outbreaks: Ethics and Global Health Governance When Facing a Pandemic
    Portland State University PDXScholar International & Global Studies Faculty Publications and Presentations International & Global Studies 3-16-2011 Developing Countries, Vaccine Access and Influenza Outbreaks: Ethics and Global Health Governance When Facing a Pandemic Shawn Smallman Portland State University, [email protected] Follow this and additional works at: https://pdxscholar.library.pdx.edu/is_fac Part of the International and Area Studies Commons, and the Public Health Commons Let us know how access to this document benefits ou.y Citation Details Smallman, Shawn, "Developing Countries, Vaccine Access and Influenza Outbreaks: Ethics and Global Health Governance When Facing a Pandemic" (2011). International & Global Studies Faculty Publications and Presentations. 4. https://pdxscholar.library.pdx.edu/is_fac/4 This Conference Proceeding is brought to you for free and open access. It has been accepted for inclusion in International & Global Studies Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. 1 Developing Countries, Vaccine Access and Influenza Outbreaks: Ethics and Global Health Governance When Facing a Pandemic Shawn Smallman Portland State University Paper presented at the annual meeting of the International Studies Association Annual Conference, "Global Governance: Political Authority in Transition", Le Centre Sheraton Montreal Hotel, Montreal, Quebec, Canada, Mar 16, 2011 2 The threat posed by influenza pandemics raises serious ethical issues, as well as questions of global health governance. In order to create pre-pandemic vaccines, global health authorities need access to virus from regional outbreaks. But because the countries where these outbreaks occur are unlikely to benefit from the vaccine, they are sometimes reluctant to share this seed stock, and may try to make proprietary arrangements with pharmaceutical companies, as briefly occurred in Indonesia.
    [Show full text]
  • Indonesia Steps up Global Health Diplomacy
    Indonesia Steps Up Global Health Diplomacy Bolsters Role in Addressing International Medical Challenges AUTHOR JULY 2013 Murray Hiebert A Report of the CSIS Global Health Policy Center Indonesia Steps Up Global Health Diplomacy Bolsters Role in Addressing International Medical Challenges Murray Hiebert July 2013 About CSIS—50th Anniversary Year For 50 years, the Center for Strategic and International Studies (CSIS) has developed solutions to the world’s greatest policy challenges. As we celebrate this milestone, CSIS scholars are developing strategic insights and bipartisan policy solutions to help decisionmakers chart a course toward a better world. CSIS is a nonprofit organization headquartered in Washington, D.C. The Center’s 220 full- time staff and large network of affiliated scholars conduct research and analysis and develop policy initiatives that look into the future and anticipate change. Founded at the height of the Cold War by David M. Abshire and Admiral Arleigh Burke, CSIS was dedicated to finding ways to sustain American prominence and prosperity as a force for good in the world. Since 1962, CSIS has become one of the world’s preeminent international institutions focused on defense and security; regional stability; and transnational challenges ranging from energy and climate to global health and economic integration. Former U.S. senator Sam Nunn has chaired the CSIS Board of Trustees since 1999. Former deputy secretary of defense John J. Hamre became the Center’s president and chief executive officer in April 2000. CSIS does not take specific policy positions; accordingly, all views expressed herein should be understood to be solely those of the author(s).
    [Show full text]
  • Indonesia's Road to Universal Health Coverage: a Political Journey
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository Health Policy and Planning, 32, 2017, 267–276 doi: 10.1093/heapol/czw120 Advance Access Publication Date: 6 September 2016 Original Article Indonesia’s road to universal health coverage: a political journey Elizabeth Pisani,1 Maarten Olivier Kok2,* and Kharisma Nugroho3 1Royal Netherlands Institute of Southeast Asian and Caribbean Studies, Institute for Health Policy and Management, Erasmus University Rotterdam, 2Institute for Health Policy and Management, Erasmus University Rotterdam, Vrije Universiteit, Amsterdam and 3Institute for Health Policy and Management, Erasmus University Rotterdam, Migunani Research, Yogyakarta *Corresponding author. Maarten Kok, De Boelelaan 1085, 1081HV Amsterdam, Phone: þ31 648254524; E-mail: [email protected] Accepted 12 August 2016 Abstract In 2013 Indonesia, the world’s fourth most populous country, declared that it would provide afford- able health care for all its citizens within seven years. This crystallised an ambition first enshrined in law over five decades earlier, but never previously realised. This paper explores Indonesia’s jour- ney towards universal health coverage (UHC) from independence to the launch of a comprehensive health insurance scheme in January 2014. We find that Indonesia’s path has been determined largely by domestic political concerns – different groups obtained access to healthcare as their socio-political importance grew. A major inflection point occurred following the Asian financial crisis of 1997. To stave off social un- rest, the government provided health coverage for the poor for the first time, creating a path dependency that influenced later policy choices.
    [Show full text]
  • COVID-19 Vaccines, Cases and Variants
    COVID-19 Critical Intelligence Unit: COVID-19 vaccines, cases and variants COVID-19 Monitor COVID-19 vaccines, cases and variants 24 June 2021 Background • Despite large numbers of vaccinations following the initial vaccine rollout, the United States, India, Chile and Europe have had a surge in COVID-19 cases. It is suspected that relaxation of public health measures, as well as the new variants of COVID-19, may have contributed to this. New variants may be more transmissible and less susceptible to antibodies produced by vaccines or previous infection.(1-6) • While preliminary research from Israel suggests that vaccination reduces transmission, vaccination alone is insufficient to contain COVID-19.(7, 8) Evidence • Viruses constantly change through mutation and, over time, new variants of a virus are expected to occur. Some variants have characteristics that have a significant impact on transmissibility, severity of disease and the effectiveness of vaccines.(9) • For SARS-CoV-2, there are currently four variants of concern as determined by the World Health Organization (WHO).(10) The WHO has recently assigned simple labels for key variants of SARS- CoV-2, included below.(11) • The four variants of concern include: o Alpha (B.1.1.7), which originated in the United Kingdom. Currently 136 countries are reporting detection of the variant. o Beta (B.1.351), which originated in South Africa. Currently 92 countries are reporting detection of the variant. o Gamma (B.1.1.28.1 or P.1), which originated in Brazil. Currently 54 countries are reporting detection of the variant. o Delta (B.1.617.2), which originated in India.
    [Show full text]
  • Genomics and Epidemiological Surveillance Stephanie W
    NEWS & ANALYSIS GENOME WATCH Genomics and epidemiological surveillance Stephanie W. Lo and Dorota Jamrozy This month’s Genome Watch highlights viral transmission, identify viral mutations D614 vari ant, which might be indicative of how genomic surveillance can provide and integrate viral data with health data2. By potential positive selection. The viral genome important information for identifying June 2020, the consortium sequenced >20,000 data were linked with patient clinical infor- and tracking emerging pathogens such SARS- CoV-2 genomes and defined transmis- mation, which showed that the G614 variant as SARS- CoV-2. sion lineages based on phylogeny. Open data might be associated with potentially higher sharing and standardized lineage definitions viral loads but not with disease severity. The timely detection and surveillance of infec- (Global Initiative on Sharing All Influenza Updated data and current global counts of tious diseases and responses to pandemics Data (GISAID)) were established to enable the spike 614 variants are available in the are crucial but challenging. Whole-genome global efforts in detecting emerging lineages COVID-19 Viral Genome Analysis Pipeline. sequencing (WGS) is a common tool for path- and mutations that are relevant for outbreak Genomic surveillance can generate a rich ogen identification and tracking, establishing control and vaccine development on an inter- source of information for tracking pathogen transmission routes and outbreak control. national level3. By the end of June 2020, >57,000 transmission and evolution on both national At the turn of 2019/20, Wu et al1 used SARS- CoV-2 genomes from around 100 dif- and international levels. More importantly, metagenomic RNA sequencing to identify the ferent countries have been deposited in the the recent application of genomics in surveil- aetiology of an at this point unknown respira- GISAID database.
    [Show full text]
  • COVID-19 and HIV: 1 MOMENT 2 EPIDEMICS 3 OPPORTUNITIES How to Seize the Moment to Learn, Leverage and Build a New Way Forward for Everyone’S Health and Rights
    UNAIDS | 2020 COVID-19 AND HIV: 1 MOMENT 2 EPIDEMICS 3 OPPORTUNITIES How to seize the moment to learn, leverage and build a new way forward for everyone’s health and rights Contents 2 Foreword 3 Key messages 4 Introduction 6 Learning from the HIV response to effectively address COVID-19 14 Leveraging the HIV infrastructure to strengthen, accelerate and sustain responses to COVID-19 19 Reimagining systems for health 25 Key recommendations for the COVID-19 response 27 References Foreword The COVID-19 pandemic has exposed the inadequacy of investments in public health, the persistence of profound economic and social inequalities and the fragility of many key global systems and approaches. Given the epic dimensions of the emergency, the world needs unity and solidarity—led by a large-scale, coordinated and comprehensive health response, and a focus on the needs of developing countries. Our decades-long fight against HIV offers essential lessons. This new report by UNAIDS examines how the experience of tackling HIV can help inform and guide effective, efficient, people-centred and sustainable COVID-19 responses. In fighting HIV, the world was confronted with a new, serious and multifaceted health crisis. Successful international efforts were rooted in a focus on innovation, respect for human rights and gender equality, community-based solutions and a commitment to leave no one behind. Decades of investment in the HIV response have created platforms that are proving useful in battling COVID-19—just as they were in responding to the 2014–2015 Ebola outbreak in western and central Africa. By being smart and strategic, we can leverage the HIV infrastructure to accelerate COVID-19 responses.
    [Show full text]
  • Biopiracy and Vaccines: Indonesia and the World Health Organization's New Pandemic Influenza Plan
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PDXScholar Portland State University PDXScholar International & Global Studies Faculty Publications International & Global Studies and Presentations 5-2013 Biopiracy and Vaccines: Indonesia and the World Health Organization's New Pandemic Influenza Plan Shawn Smallman Portland State University, [email protected] Let us know how access to this document benefits ouy . Follow this and additional works at: http://pdxscholar.library.pdx.edu/is_fac Part of the International and Area Studies Commons, and the Public Health Commons Citation Details Smallman, S. (2013). Biopiracy and vaccines: Indonesia and the World Health Organization's new Pandemic Influenza Plan. Journal Of International & Global Studies, 4(2), 20-36. This Article is brought to you for free and open access. It has been accepted for inclusion in International & Global Studies Faculty Publications and Presentations by an authorized administrator of PDXScholar. For more information, please contact [email protected]. Biopiracy and vaccines: Indonesia and the World Health Organization’s new Pandemic Influenza Plan Shawn Smallman, PhD International Studies Portland State University [email protected] Abstract Viral samples of avian influenza are essential to preparing pre-pandemic vaccines. In 2007, the conflicting interests of the developed and developing nations led Indonesia to briefly stop sharing viral samples. The result was a struggle in which the two blocs argued for different paradigms for viral sample sharing. The first paradigm, articulated by the developed world, depicted the issue as one of health security, in which international law mandated the sharing of viral samples. The second paradigm, advanced by the developing world, depicted viral sample sharing as a form of biopiracy, which violated countries’ sovereign control of their biological resources.
    [Show full text]
  • SARS-Cov-2 Variants ACKNOWLEDGEMENTS
    SARS-CoV-2 variants ACKNOWLEDGEMENTS This report was developed by PHG Foundation for FIND (the Foundation for Innovative New Diagnostics). The work was supported by Unitaid and UK aid from the British people. We would like to thank all those who contributed to the development and review of this report. Lead writers Chantal Babb de Villiers (PHG Foundation) Laura Blackburn (PHG Foundation) Sarah Cook (PHG Foundation) Joanna Janus (PHG Foundation) Reviewers Devy Emperador (FIND) Jilian Sacks (FIND) Marva Seifert (FIND/UCSD) Anita Suresh (FIND) Swapna Uplekar (FIND) Publication date: 11 March 2021 URLs correct as of 4 March 2021 SARS-CoV-2 variants CONTENTS 1 Introduction ............................................................................................................................ 3 2 SARS-CoV-2 variants and mutations .................................................................................... 3 2.1 Definitions of variants of concern ...................................................................................... 4 2.2 Initial variants of concern identified ................................................................................... 5 2.3 Variants of interest ............................................................................................................ 7 3 Impact of variants on diagnostics ........................................................................................ 7 3.1 Impact of variants of concern on diagnostics ...................................................................
    [Show full text]
  • WHO Survey on the Sharing of Genetic Sequence Data Of
    WHO Survey on the Sharing of Genetic Sequence Data of Influenza Viruses with Human Pandemic Potential Results and Analysis of data received 27 April 2016 Table of Contents Acknowledgement .................................................................................................................................. 3 Acronyms ................................................................................................................................................ 4 Executive Summary ................................................................................................................................. 5 Background ............................................................................................................................................. 8 Methodology Summary .......................................................................................................................... 9 IVPP GSD Sharing in Numbers (as of October 2014)............................................................................. 10 Survey Results ....................................................................................................................................... 11 1. Mechanisms for sharing of IVPP GSD........................................................................................ 11 2. Ease of sharing .......................................................................................................................... 13 3. Systematic sharing ...................................................................................................................
    [Show full text]
  • Avian Influenza A(H10N7) Virus–Associated Mass Deaths Among Harbor Seals
    Article DOI: http://dx.doi.org/10.3201/eid2104.141675 Avian Influenza A(H10N7) Virus–Associated Mass Deaths among Harbor Seals Technical Appendix Technical Appendix Table. Details of hemagglutinin sequences shown in the Figure* Isolate name Accession no. Online database A/seal/Germany/EMC-1/2014(H10N7) EPI544351 GISAID EpiFlu A/mallard/Netherlands/1/2014(H10N7) EPI552751 GISAID EpiFlu A/mallard/Sweden/133546/2011(H10N4) CY183991.1 GenBank A/domestic duck/RepublicofGeorgia/2/2010(H10N7) CY185457.1 GenBank A/domestic duck/RepublicofGeorgia/1/2010(H10(N7) CY185449.1 GenBank A/mallard/Sweden/104746/2009(H10N1) CY183855.1 GenBank A/mallard/Sweden/105465/2009(H10N1) CY183927.1 GenBank A/mallard/Sweden/102260/2009(H10N1) CY183847.1 GenBank A/mallard/Sweden/105323/2009(H10N1) CY183887.1 GenBank A/mallard/Sweden/105402/2009(H10N1) CY183911.1 GenBank A/mallard/Sweden/105522/2009(H10N1) JX566079.1 GenBank A/mallard/Netherlands/50/2010(H10N7) EPI552752 GISAID EpiFlu A/mallard/Netherlands/47/2010(H10N7) EPI552753 GISAID EpiFlu A/mallard/Republic of Georgia/14/2011(H10N7) CY185689.1 GenBank A/mallard/Republic of Georgia/15/2011(H10N7) CY185385.1 GenBank A/northern pintail/Egypt/EMC-1/2012(H10N7) EPI552754 GISAID EpiFlu A/mallard/Egypt/EMC-4/2012(H10N7) EPI552755 GISAID EpiFlu A/mallard/Netherlands/1/2012(H10N7) EPI552756 GISAID EpiFlu A/shoveler/Egypt/01198-NAMRU3/2007(H10N7) EPI372402† GISAID EpiFlu A/Jiangxi-Donghu/346/2013(H10N8) EPI497477‡ GISAID EpiFlu A/chicken/Jiangxi/102/2013(H10N8) EPI530542§ GISAID EpiFlu *We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiFluTM database on which this research is based.
    [Show full text]
  • Investigation of Novel SARS-Cov-2 Variant
    SARS-CoV-2 variant data update, England Version 10 6 August 2021 This briefing provides an update on previous data located in technical and variant data update briefings and updates up to 23 July 2021. 1 Investigation of SARS-CoV-2 Variants of Concern. Version 10. Contents Contents .............................................................................................................................. 2 Data on individual variants .................................................................................................. 5 Alpha ............................................................................................................................... 5 Beta ................................................................................................................................. 9 Gamma .......................................................................................................................... 13 Zeta ............................................................................................................................... 17 Eta ................................................................................................................................. 20 VUI-21FEB-04 (B.1.1.318) ............................................................................................ 23 Theta ............................................................................................................................. 26 Kappa ...........................................................................................................................
    [Show full text]
  • Cities and Public Health Crises Report
    REPORT OF THE INTERNATIONAL CONSULTATION 29-30 OCTOBER 2008 LYON, FRANCE CITIES AND PUBLIC HEALTH CRISES REPORT REPORT OF THE INTERNATIONAL CONSULTATION 29-30 OCTOBER 2008 LYON, FRANCE CITIES AND PUBLIC HEALTH CRISES © World Health Organization 2009 WHO/HSE/IHR/LYON/2009.5 All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. REPORT OF THE INTERNATIONAL CONSULTATION 29-30 OCTOBER 2008 LYON,
    [Show full text]